Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 11/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22052099 | 1.00 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21740248 | 0.91 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL25038229 | 0.91 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL22051520 | 0.91 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739579 | 0.89 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21740283 | 0.89 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739571 | 0.89 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL22052128 | 0.86 | — | — | |
| SCHEMBL22052822 | 0.85 | SETD2 (0.32) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739618 | 0.85 | SETD2 (0.35) | SETD2NSD2CYP2C8DRD2HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |